FI91362B - Förfarande för stabilisering av humanleukocyter för lagring och förfarande för framställning av en komposition fri från röda blodkroppar - Google Patents
Förfarande för stabilisering av humanleukocyter för lagring och förfarande för framställning av en komposition fri från röda blodkroppar Download PDFInfo
- Publication number
- FI91362B FI91362B FI882944A FI882944A FI91362B FI 91362 B FI91362 B FI 91362B FI 882944 A FI882944 A FI 882944A FI 882944 A FI882944 A FI 882944A FI 91362 B FI91362 B FI 91362B
- Authority
- FI
- Finland
- Prior art keywords
- storage
- composition
- plasma
- leukocytes
- gelatin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 21
- 210000000265 leukocyte Anatomy 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 230000000087 stabilizing effect Effects 0.000 title claims 2
- 210000003743 erythrocyte Anatomy 0.000 title description 5
- 108010010803 Gelatin Proteins 0.000 claims abstract description 22
- 239000008273 gelatin Substances 0.000 claims abstract description 22
- 229920000159 gelatin Polymers 0.000 claims abstract description 22
- 235000019322 gelatine Nutrition 0.000 claims abstract description 22
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 22
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 21
- 239000000872 buffer Substances 0.000 claims abstract description 19
- 238000007710 freezing Methods 0.000 claims abstract description 10
- 230000008014 freezing Effects 0.000 claims abstract description 10
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 7
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Dentistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Freezing, Cooling And Drying Of Foods (AREA)
- Packages (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (7)
1. Förfarande för stabilisering av frän blod er-hällna humanleukocyter för lagring utan frysning, k ä n - 5 netecknat därav, att leukocyterna suspenderas i en giftfri buffert som innehäller gelatin och plasma, var-vid mängden gelatin är ätminstone 1 vikt-% av komposi-tionens totalmängd och mindre än den mängd som behövs för att kompositionen skall utfalla som en gel vid en tempera- 10 tur av 40 °C eller högre än denna, och mängden plasma är frän 25 vikt-% tili 90 vikt-% av kompositionens totalmängd .
2. Förfarande enligt patentkrav 1, k ä n netecknat därav, att det som ett ytterligare steg 15 innehäller lagring av nämnda suspension utan frysning vid en temperatur under 25 °C för en tid av ätminstone fem dygn.
3. Förfarande enligt patentkrav 2, k ä n netecknat därav, att lagringen utförs vid en tempera- 20 tur under 8 eC.
4. Förfarande enligt patentkrav 2, k ä n netecknat därav, att pH hos bufferten är inom omrädet 6,1 - 8,0, lagringen utförs vid en temperatur under 8 °C, och antalet leukocyter i suspensionen är frän 1 x 107 tili 25. x 10* per milliliter.
5. Förfarande enligt nägot av patentkraven 1-4, kännetecknat därav, att leukocyterna är granu-locyter.
6. Förfarande för framställning av en komposition 30 fri frän röda blodkroppar, kännetecknat därav, att leukocyter suspenderas i en giftfri buffert som innehäller gelatin och plasma, varvid mängden gelatin är ätminstone l vikt-% av kompositionens totalmängd och mindre än den mängd som behövs för att kompositionen skall 35 utfalla som en gel vid en temperatur av 40 °C eller högre 91362 än denna, och mängden plasma är frän 25 vikt-% tili 90 vikt-% av kompositionens totalmängd.
7. Förfarande enligt patentkrav 6, känne-t e c k n a t därav, att leukocyterna är granulocyter.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67607184A | 1984-11-29 | 1984-11-29 | |
| US67607184 | 1984-11-29 | ||
| US06/758,514 US4639373A (en) | 1984-11-29 | 1985-07-24 | Stabilization of granulocytes |
| US75851485 | 1985-07-24 | ||
| US8602275 | 1986-10-22 | ||
| PCT/US1986/002275 WO1988003028A1 (en) | 1984-11-29 | 1986-10-22 | Stabilization of leukocytes |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI882944A0 FI882944A0 (sv) | 1988-06-20 |
| FI882944A FI882944A (sv) | 1988-06-20 |
| FI91362B true FI91362B (sv) | 1994-03-15 |
| FI91362C FI91362C (sv) | 1994-06-27 |
Family
ID=27101470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI882944A FI91362C (sv) | 1984-11-29 | 1988-06-20 | Förfarande för stabilisering av humanleukocyter för lagring och förfarande för framställning av en komposition fri från röda blodkroppar |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4639373A (sv) |
| EP (1) | EP0288467B1 (sv) |
| JP (1) | JPH0686384B2 (sv) |
| AT (1) | ATE79758T1 (sv) |
| AU (1) | AU589237B2 (sv) |
| DE (1) | DE3686584T2 (sv) |
| DK (1) | DK338888A (sv) |
| FI (1) | FI91362C (sv) |
| NO (1) | NO175517C (sv) |
| WO (1) | WO1988003028A1 (sv) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639373A (en) * | 1984-11-29 | 1987-01-27 | New England Medical Center Hospitals, Inc. | Stabilization of granulocytes |
| US4936963A (en) * | 1987-05-27 | 1990-06-26 | Abbott Laboratories | Polycationic buffers and method for gel electrophoresis of nucleic acids |
| IT1217938B (it) * | 1988-06-28 | 1990-03-30 | Girolamo Sirchia | Procedimento per la preparazione e la conservazione di concentrati eritrocitari e piastrinici |
| US5211960A (en) * | 1988-11-29 | 1993-05-18 | Scripps Clinic And Research Foundation | Stabilization of leukocytes |
| US4923797A (en) * | 1988-11-29 | 1990-05-08 | President & Fellows Of Harvard College | Stabilization of leukocytes |
| GB8830197D0 (en) * | 1988-12-23 | 1989-02-22 | Univ Dundee | Tissue preservation medium |
| WO1996014740A1 (en) * | 1992-03-02 | 1996-05-23 | Cerus Corporation | Synthetic media for blood components |
| US5459030A (en) * | 1992-03-02 | 1995-10-17 | Steritech, Inc. | Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen |
| EP1002538A3 (en) * | 1992-06-25 | 2000-07-19 | SCHEER, David | Stem cell and lymphocyte storage |
| CA2141803C (en) * | 1992-08-07 | 2003-06-17 | Lily Lin | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
| US6413713B1 (en) * | 1998-10-30 | 2002-07-02 | Hyperbaric Systems | Method for preserving blood platelets |
| US7112576B1 (en) | 1999-12-10 | 2006-09-26 | Regents Of The University Of Minnesota | Compositions and methods for cryopreservation of peripheral blood lymphocytes |
| WO2003000052A1 (en) * | 2001-06-26 | 2003-01-03 | Human Biosystems | Preservation of blood platelets at cold temperatures |
| CA2522941A1 (en) * | 2003-04-23 | 2004-11-04 | Human Biosystems | Improved methods and solutions for storing donor organs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390619A (en) * | 1981-09-28 | 1983-06-28 | James Clifford Haight | Leukocyte or platelet storage using ion-exchange resins |
| US4639373A (en) * | 1984-11-29 | 1987-01-27 | New England Medical Center Hospitals, Inc. | Stabilization of granulocytes |
-
1985
- 1985-07-24 US US06/758,514 patent/US4639373A/en not_active Expired - Lifetime
-
1986
- 1986-10-22 JP JP61506071A patent/JPH0686384B2/ja not_active Expired - Fee Related
- 1986-10-22 AT AT86907055T patent/ATE79758T1/de not_active IP Right Cessation
- 1986-10-22 EP EP86907055A patent/EP0288467B1/en not_active Expired - Lifetime
- 1986-10-22 AU AU66279/86A patent/AU589237B2/en not_active Ceased
- 1986-10-22 WO PCT/US1986/002275 patent/WO1988003028A1/en active IP Right Grant
- 1986-10-22 DE DE8686907055T patent/DE3686584T2/de not_active Expired - Fee Related
-
1988
- 1988-06-20 FI FI882944A patent/FI91362C/sv not_active IP Right Cessation
- 1988-06-21 DK DK338888A patent/DK338888A/da not_active Application Discontinuation
- 1988-06-21 NO NO882731A patent/NO175517C/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU6627986A (en) | 1988-05-25 |
| WO1988003028A1 (en) | 1988-05-05 |
| NO175517B (no) | 1994-07-18 |
| JPH01501469A (ja) | 1989-05-25 |
| EP0288467A4 (en) | 1990-01-08 |
| ATE79758T1 (de) | 1992-09-15 |
| AU589237B2 (en) | 1989-10-05 |
| EP0288467B1 (en) | 1992-08-26 |
| NO882731L (no) | 1988-08-19 |
| DK338888D0 (da) | 1988-06-21 |
| FI882944A0 (sv) | 1988-06-20 |
| DE3686584T2 (de) | 1993-03-04 |
| US4639373A (en) | 1987-01-27 |
| EP0288467A1 (en) | 1988-11-02 |
| DE3686584D1 (de) | 1992-10-01 |
| FI91362C (sv) | 1994-06-27 |
| FI882944A (sv) | 1988-06-20 |
| NO175517C (no) | 1994-10-26 |
| NO882731D0 (no) | 1988-06-21 |
| JPH0686384B2 (ja) | 1994-11-02 |
| DK338888A (da) | 1988-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI91362B (sv) | Förfarande för stabilisering av humanleukocyter för lagring och förfarande för framställning av en komposition fri från röda blodkroppar | |
| CA1254838A (en) | Prolonged storage of red blood cells | |
| JP2000516963A (ja) | 酸素除去・添加剤使用による赤血球長期保存法 | |
| JP2002516254A (ja) | ヒト赤血球の低温保存 | |
| JP4927282B2 (ja) | 血小板の保存のための組成物 | |
| Hak et al. | Toxic effects of DMSO on cultured beating heart cells at temperatures above zero | |
| EP0647267B1 (en) | Stem cell storage | |
| Owens et al. | Cryopreserved platelets have decreased adhesive capacity | |
| Lionetti et al. | Factors affecting the stability of cryogenically preserved granulocytes | |
| US5369001A (en) | Stabilization of leukocytes | |
| Hardeman et al. | Storage of human blood platelets | |
| White et al. | Platelet spherocytosis: a new bleeding disorder | |
| US4199954A (en) | Method of storing physiological material | |
| CA1270446A (en) | Stabilization of leukocytes | |
| Wagner et al. | Red blood cell stabilization reduces the effect of cell density on recovery following cryopreservation | |
| WO2020247702A1 (en) | Red blood cell storage solutions, additives, and methods for improving the storage of red blood cells using inorganic pyrophosphates | |
| Derrick et al. | Studies of the Metabolic Integrity of Human Red Blood Cells After Cryopreservation: II. Effects of Low‐glycerol‐Rapid‐freeze Preservation on Glycolysis | |
| Mabry et al. | Differential phagocytosis of normal, trypsinized and virus-treated human and rabbit erythrocytes by macrophages in tissue culture | |
| Moore et al. | Post‐Thaw Storage at 4° C of Previously Frozen Red Cells with Retention of 2, 3‐DPG 1 | |
| Korsak et al. | Evaluation of two distinct cryoprotectants for cryopreservation of human red blood cell concentrates | |
| Hardeman | The effect of continuous dialysis on platelet preservation | |
| Dayian et al. | ADP-aggregation in platelets frozen with glycerol | |
| French et al. | Ultrastructural analysis of preserved dog granulocytes | |
| Charles et al. | Advances in Hematology and Oncology Research | |
| Blanchaer et al. | GLUCOSE UTILIZATION IN BLOOD CELLS SURVIVING STORAGE AT− 79° C. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed |
Owner name: NEW ENGLAND MEDICAL CENTER HOSPITALS |